SESSION TITLE: Chest Infections Posters
SESSION TYPE: Original Investigation Posters
PRESENTED ON: October 18-21, 2020
PURPOSE: To understand the characteristics, comorbid conditions, and clinical outcome of patients hospitalized with coronavirus disease 2019 (COVID-19) in the US.
METHODS: This analysis included data from 7 acute care hospitals in the Mount Sinai Health System, which serves approximately 3.5 million patients in the New York metropolitan area. We included all consecutively hospitalized adults between March 1st to May 10th, 2020, who had a positive polymerase-chain-reaction testing (RT-PCR) for SARS-CoV-2 infection by nasopharyngeal or oropharyngeal swab and who had a completed hospital course (discharged alive or died) at time of analysis, May 15th, 2020. Initial testing for SARS-CoV-2 was conducted by the New York State Department of Health until March 15, 2020, when internal testing was available at the Mount Sinai laboratory. Patients who died or who were transferred to another facility within 24 hours after hospital admission were excluded from the analysis. The study used de-identified data from the Mount Sinai Data Warehouse (MSDW) ‒ “COVID-19 Project”. The Mount Sinai COVID-19 Clinical Research Protocol Review Committee approved this study and the institutional review board of Icahn School of Medicine at Mount Sinai exempted the research project from approval as it is a retrospective review of already collected, de-identified data.
RESULTS: A total of 4,903 consecutive admissions with RT-PCR confirmed COVID-19 were admitted to seven Mount Sinai Hospitals between March 1st to May 10th, 2020. Among these 4313 patients 1270 died during their hospitalization while 3043 were successfully discharged as demonstrated in Figure 1. The mean age of the study population was 65.08 ± 16.8, with a male predominance (56.6%) as outlined in Table 1. Hypertension, diabetes, chronic kidney disease, smokers, a history of chronic obstructive pulmonary disease, and a history of smoking were significantly more common among non-survivors (all p<0.05). Inflammatory biomarkers were examined in patients on admission (Table 1). Survivors were more likely to have a lower mean level of CRP, D-dimer, procalcitonin.
CONCLUSIONS: In this case series, we described our early clinical experience with COVID-19. We illustrated the characteristics, comorbid conditions, and clinical outcome of sequentially hospitalized patients with confirmed COVID-19 in New York City.
CLINICAL IMPLICATIONS: In this case series that included 4313 patients hospitalized with COVID-19 in New York City, 56% were male and 45% were Hispanics. The most common comorbidities were hypertension (35%) and diabetes (23%), and 56% had a Charlson Comorbidity Index of 3 or greater. While 72% of hospitalized patients had moderate disease and 13% required intubation. Overall, 70.5% (n=3043) of Covid-19 patients were discharged and 29.4% (n=1270) died at the time of analysis.
DISCLOSURES: No relevant relationships by Yasmin Herrera, source=Web Response
No relevant relationships by Kam Sing Ho, source=Web Response
No relevant relationships by Archana Pattupara, source=Web Response
No relevant relationships by Joseph Poon, source=Web Response
No relevant relationships by Justin Poon, source=Web Response
No relevant relationships by David Steiger, source=Web Response